Molecular Partners, Roche in cancer deal

Molecular Partners AG (Schlieren, Switzerland) and Roche (SIX:ROG; OTCQX: RHHBY) partnered to generate conjugates of toxic agents from Roche with Molecular Partners' designed ankyrin repeat proteins (DARPins) against a set of undisclosed targets for cancer. Molecular Partners will receive undisclosed research funding and up to CHF55 million ($60.2 million) in upfront and initiation payments. The company is also eligible for over CHF1 billion ($1.1 billion) in milestones, plus tiered royalties. Roche has an undisclosed "limited number of options" to select compounds to develop and commercialize. ...